Evaluation of compliance, persistence, safety profile and satisfaction to monthly single-pill treatment regimen of ibandronic acid 150 mg and cholecalciferol 22,400 IU among postmenopausal women with osteoporosis

The monthly single-pill treatment regimen of ibandronic acid 150 mg and cholecalciferol 22,400 IU demonstrated high treatment compliance, persistence and patient satisfaction with a favorable safety profile and was well tolerated after six months of treatment.